Journal of Neuro-Oncology

, Volume 4, Issue 1, pp 5–16

Apparent glucose utilization in Walker 256 metastatic brain tumors

Authors

  • Ronald G Blasberg
    • Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer TreatmentNational Cancer Institute
  • Mami Shinohara
    • Laboratory of Cerebral Metabolism, National Institute of Mental HealthNIH
    • Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer TreatmentNational Cancer Institute
  • William R Shapiro
    • Department of NeurologyMemorial Sloan-Kettering Cancer Center and Cornell University
    • Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer TreatmentNational Cancer Institute
  • Clifford S Patlak
    • Theoretical Statistics and Mathematics Branch, National Institute of Mental HealthNIH
    • Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer TreatmentNational Cancer Institute
  • Karen D Pettigrew
    • Theoretical Statistics and Mathematics Branch, National Institute of Mental HealthNIH
    • Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer TreatmentNational Cancer Institute
  • Joseph D Fenstermacher
    • Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer TreatmentNational Cancer Institute
Article

DOI: 10.1007/BF02157996

Cite this article as:
Blasberg, R.G., Shinohara, M., Shapiro, W.R. et al. J Neuro-Oncol (1986) 4: 5. doi:10.1007/BF02157996

Abstract

Regional rates of apparent glucose utilization (GU) in metastatic Walker 256 (WL-256) brain tumors produced by the intracarotid injection of WL-256 tumor cells in rats were measured using14C-deoxyglucose and quantitative aroradiography. Apparent glucose utilization was uniform within individual small and medium size tumors without necrosis, varied considerably among different tumors within this group, and did not correlate with tumor size or location. High values of GU in medium and large-size tumors correlated with viable-appearing tissue in contrast to necrotic tissue and were always 1.3 to 3 times higher than that of adjacent and contralateral nontumorous brain. The apparent net extraction of glucose (E n * ) in viable tumor regions was estimated to be several fold higher than that in remote brain tissue; analysis of this data for medium and large tumors indicates that the calculated values of GU and E n * overestimate the actual rates of utilization and net extraction of glucose. Local cerebral glucose utilization (LCGU) was higher than normal adjacent to small tumors and lower than normal adjacent to large tumors. The LCGU in many gray-matter structures remote from the intracerebral tumors was reduced and roughtly proportional to the metastatic tumor burden. The comparatively high uptake of 2-deoxyglucose by viable tumor cells has diagnostic and localization value and suggests that appropriate glucose analogues could be developed to produce a tumor-selective inhibition of glycolysis and tumoricidal effect.

Key words

glucose utilization Walker 256 tumors metastatic brain tumors deoxyglucose quantitative autoradiography

Copyright information

© Martinus Nijhoff Publishers 1986